Investment Rating - The report maintains an "Overweight" rating for the medical consumables industry and offline pharmacy sector [5][6]. Core Insights - The medical consumables market is expected to recover, with positive performance anticipated for innovative high-value consumables due to factors such as aging population, increased demand for medical services, and improved domestic production rates [3]. - The offline pharmacy industry is transitioning from a period of rapid expansion to a focus on operational efficiency and service value, driven by policy guidance that encourages industry consolidation [4]. Summary by Sections Medical Consumables Industry - The market is experiencing a recovery in confidence, with expectations for improved performance in high-value consumables [3]. - Investment focus areas include: 1. Performance reversal in segments like orthopedic consumables, exemplified by companies such as Weigao Orthopedics [5]. 2. Increased market penetration of low-penetration consumables, particularly in high-end innovative fields [5]. 3. Expansion into overseas markets, with orthopedic and interventional consumables leading the way [5]. Offline Pharmacy Industry - The industry is set for accelerated consolidation, moving towards high-quality development characterized by operational efficiency and resource optimization among leading brands [4]. - Key companies to watch include those with advantages in compliance, supply chain, and digital management, such as Yifeng Pharmacy [6]. Market Performance - The medical consumables sector reported a 17.02% increase in the past year, indicating a strong recovery compared to the broader market [17]. - The report highlights the performance of leading companies in the medical consumables sector, with significant growth observed in companies like Hualan Biological Engineering and ZhenDe Medical [20][25].

Industry Overview - The banking sector shows signs of recovery in corporate loan growth, with a year-on-year increase of 8.9% in corporate loans by the end of Q4 2025, reflecting a 0.7 percentage point rise from the previous quarter [2] - Infrastructure and service industries are experiencing a rebound in medium to long-term loans, with industrial medium to long-term loans growing by 8.4%, which is 2.2 percentage points higher than the overall loan growth [3] - The growth in loans for infrastructure-related industries reached 6.9%, while service industry loans increased by 7.8%, indicating a positive trend in these sectors [3] Consumer Loans - Household loans showed a modest year-on-year growth of 0.5% by the end of Q4 2025, with operational loans contributing significantly at a 4.0% increase [4] - Consumer loans, excluding personal housing loans, also saw a slight increase of 0.7%, suggesting a stable but weak growth in retail lending [4] Investment Recommendations - With fiscal expansion and the effectiveness of policy tools, corporate loan issuance is expected to improve, leading to a potential "New Year" boost in bank credit [5] - The report highlights the significant value of high dividend yields in bank stocks, suggesting that under a balanced market style, there is potential for valuation recovery [5] - Recommended banks include major state-owned banks and those with strong operational flexibility, such as Industrial and Commercial Bank of China, Bank of China, and others [5]

Investment Rating - Industry rating: Buy (maintained) [8] Core Insights - The central price of copper is determined by macroeconomic factors (β) and real demand (α), where the price "central" is not influenced by short-term supply and demand but rather by the macro environment and sustainable real demand [2] - Macroeconomic factors (β) include real interest rates, dollar liquidity, global credit expansion, and risk appetite, which act as amplifiers for all commodities, influencing market valuations [3] - Real demand (α) emphasizes long-term trends and sustainability, focusing on indicators such as grid investment, energy transition, and manufacturing capital expenditure, which are not influenced by short-term financial conditions [4] - The supply side of copper is characterized by long cycles and constraints, making it a slow variable that does not significantly affect the price central [5] Market Dynamics - Recent declines in copper prices are driven by macroeconomic factors (β) rather than real demand (α), indicating a market-wide revaluation rather than a fundamental deterioration in any specific sector [6] - The current market phase is transitioning from a period of β shocks to a phase where the impact of these shocks is expected to diminish, leading to a reassessment of real demand [11] Price Outlook - Short-term trading logic is influenced by expectations of Federal Reserve leadership changes and tightening liquidity, suggesting caution in declaring a market bottom [12] - The medium-term outlook for copper prices will depend on whether real demand (α) remains intact, with key indicators being global grid investment and capital expenditure in energy and manufacturing [12] Investment Recommendations - Current strategy should focus on structural defense under β pressure while waiting for a revaluation of α, with a preference for aluminum over copper in the short term [13][15] - For copper, patience is advised, with a focus on high-certainty domestic companies over more volatile overseas firms, and a preference for mining companies over processing firms [15]

1. Report Industry Investment Rating No relevant information provided. 2. Core Viewpoints of the Report - As of January 31, 2026, the total number of funds in the market increased by 104 to 13,722, while the total net asset value decreased by 452.4 billion yuan to 37.22 trillion yuan. Growth - type funds outperformed value - type funds in January 2026 [3][7]. - As of January 31, 2026, there were 1,430 ETFs in the Shanghai and Shenzhen stock markets, an increase of 28 from the previous period. The total asset management scale decreased by 555.748 billion yuan to 5.46 trillion yuan, and the total share decreased by 92.652 billion shares to 3.28 trillion shares. Commodity - type ETFs had a higher overall return in January, while bond - type ETFs had the worst performance [4][18]. - The industry ETF rotation strategy based on main funds and the PB - ROE framework both achieved positive excess returns compared to the CSI 300 Index in January 2026 and since 2023 [5][40][50]. 3. Summary According to Relevant Catalogs 3.1 Fund Market Tracking 3.1.1 Market Overview - As of January 31, 2026, the number of funds increased by 104, and the total net asset value decreased by 452.4 billion yuan. Hybrid, bond, and stock - type funds had the highest proportion in terms of quantity, while money - market, bond, and stock - type funds had the highest proportion in terms of scale [7]. - In January 2026, the number of stock - type funds increased by 49, and the scale of stock - type and bond - type funds decreased by 552.001 billion yuan and 88.818 billion yuan respectively [11]. 3.1.2 Fund Performance - From January 1 to 31, 2026, the returns of value, balanced, and growth fund indexes were 3.92%, 6.10%, and 7.02% respectively, all outperforming the CSI 300 Index. Growth - type funds outperformed value - type funds [13]. - The differences among large - cap, mid - cap, and small - cap fund indexes were small in January 2026, with mid - cap funds slightly outperforming large - cap and small - cap funds, and all outperforming the CSI 300 Index [13]. - The median return of all funds in January 2026 was 2.53%, and 94.84% of funds achieved positive returns. The top - performing fund was SDIC UBS Silver Futures A, with a gain of 61.60% in both January and year - to - date [16]. 3.2 ETF Market Tracking 3.2.1 ETF New Products - In January 2026, 33 ETFs were newly listed, including 3 science - and - technology innovation board chip ETFs and 30 other stock - type ETFs. 27 ETFs were newly established, with a total issuance scale of 16.57 billion yuan [20]. 3.2.2 ETF Product Classification Performance - Commodity - type ETFs had a median return of 18.61% in January, bond - type ETFs had the lowest median return of 0.25%, and stock - type ETFs had a median return of 4.74%, outperforming cross - border ETFs. Stock - type ETFs had the highest internal deviation in January [4][24]. - Among stock - type ETFs in January, gold - related and mining ETFs performed well, while bank - related ETFs performed poorly. The average share change of stock - type ETFs was a decrease of 108.9666 million shares, with chemical and software ETFs having significant share increases and CSI 300 and SSE 50 ETFs having significant share decreases [25]. - Among bond - type ETFs in January, the convertible bond ETF had the highest increase of 5.90%, and the science - innovation bond ETF had a decrease of 0.01%. As of January 31, 2026, the Haifutong CSI Short - Term Financing ETF had the largest scale of 70.223 billion yuan [29]. - Among cross - border ETFs in January, the China - South Korea Semiconductor ETF had the highest increase of 45.09%, and the Hong Kong Stock Connect Medical ETF had the highest decrease of 4.20%. The year - to - date performance was similar [31]. - Among commodity - type ETFs in January, the gold ETF had an increase of 19.11%, and the soybean meal ETF had the smallest increase of 1.69%. As of January 31, 2026, the Huaan Gold ETF had the largest scale of 93.985 billion yuan [35]. 3.3 ETF Strategy Tracking 3.3.1 Industry ETF Rotation Based on Main Funds - The strategy focused on non - ferrous metals, non - banking finance, and steel in January 2026. The cumulative return in January 2026 was 9.01%, with an excess return of 7.36% compared to the CSI 300 Index. Since 2023, the cumulative return was 61.84%, with an excess return of 40.28% compared to the CSI 300 Index [5][40][42]. 3.3.2 Industry ETF Rotation under the PB - ROE Framework - The strategy focused on communication, agriculture, forestry, animal husbandry, and fishery, and transportation in January 2026. The cumulative return in January 2026 was 2.83%, with an excess return of 1.18% compared to the CSI 300 Index. Since 2023, the cumulative return was 29.03%, with an excess return of 7.47% compared to the CSI 300 Index [5][50][51]. 3.4 Investment Recommendations - For the industry preference of main funds in February 2026, the steel, coal, and non - ferrous metal industries are favored, and the corresponding ETFs are their industry ETFs. - Based on the industry PB - ROE situation and supplementary indicators, the ETF rotation strategy under the PB - ROE framework recommends paying attention to the non - ferrous metal, transportation, and public utilities industries in February, and the corresponding ETFs are their industry ETFs [6][57].

Macro Strategy - In January 2026, PMI fell below the threshold, with manufacturing PMI at 49.3%, non-manufacturing PMI at 49.4%, and composite PMI at 49.8%, indicating a decline in economic prosperity [2] - The production index was at 50.6%, indicating manufacturing expansion, while the new orders index dropped to 49.2%, reflecting a decrease in market demand [2] - Industries such as agricultural food processing and aerospace equipment showed production and new orders indices above 56.0%, while sectors like petroleum and automotive saw indices below the threshold, indicating a slowdown in market demand [2] Stock Market Overview - A-shares experienced fluctuations after a "good start," with the Shanghai Composite Index down 0.44% and the Shenzhen Component down 1.62% from January 26 to January 30, 2026 [3] - The market's volatility was attributed to a strong dollar affecting gold and other previously rising sectors, leading to a broad decline in indices [3][4] - The overall market trend remains strong, supported by the central bank's policies and the expectation of continued economic stability in 2026 [7] Industry Analysis: Non-ferrous Metals and New Materials - The rare earth magnetic materials sector saw a slight increase of 0.16%, outperforming the benchmark [9] - Domestic light rare earth concentrate prices stabilized, while medium and heavy rare earth prices declined, with praseodymium and neodymium prices showing weak fluctuations [10] - The supply side remains tight, with market demand expected to support high rare earth prices, while the demand for downstream applications like new energy vehicles is showing signs of marginal decline [11] Investment Recommendations - The non-ferrous metals sector is rated as "overweight," with expectations of stable demand and pricing trends, particularly in the rare earth segment [11] - Focus on upstream rare earth resource companies and downstream magnetic material firms with strong customer structures and growth potential [12]

证券研究报告 2026 年 02 月 01 日 湘财证券研究所 行业研究 房地产行业周报 1 月二手房成交强于新房 相关研究： 1.《周度观点：楼市进入传统淡季， 政策加码预期较强》 2026.1.25 ❑ 核心城市：1 月核心城市二手房成交同比增长，新房成交较弱 北京：根据 Wind 数据，北京近一周（1.24-1.30）二手房日均成交套数为 578 套（同比+397%），新房成交套数为 85 套(同比+565%)，同比大幅增长 主要受春节错位影响。若剔除春节因素，近一周二手房成交同比去年农历 同期+3.9%，新房成交同比去年农历同期-32.5%。单月来看，1 月二手房成 交套数同比+17.4%，新房成交同比-12.5%。 上海：根据 Wind 数据，上海近一周（1.24-1.30）二手房日均成交 797 套（同 比+806%），新房日均成交 221 套（同比+525%）。剔除春节错位影响后， 近一周二手房、新房日均成交较去年农历同期分别+1%、-27%。单月来看， 1 月二手房、新房成交套数同比分别为+17.6%、-5.3%，尤其是二手房连续 三个月保持在 2 万套以上的荣枯线，市场较为活跃。 深圳：根据 ...

Core Insights - The A-share market experienced wide fluctuations after the "opening red" in January, with major indices showing mixed performance [2][10] - The manufacturing PMI fell below the boom-bust line in January, indicating a decline in economic activity [6][27] - The report suggests a long-term bullish outlook for the A-share market supported by favorable monetary policies and economic recovery [8][31] Market Performance - During the week of January 26-30, 2026, the Shanghai Composite Index fell by 0.44%, the Shenzhen Component dropped by 1.62%, and the ChiNext Index saw a slight decline of 0.09% [3][10] - The largest weekly fluctuation was observed in the Sci-Tech Innovation Board Index, which experienced a 6.67% swing [10] - The overall market trend reflects increased volatility due to a stronger dollar and high index levels, leading to a demand for consolidation [13] Industry Analysis - Among the 31 first-level industries, the oil and petrochemical sector and telecommunications led with gains of 7.95% and 5.83%, respectively, while the defense and military industry and power equipment saw declines of -7.69% and -5.10% [4][20] - In the second-level industries, precious metals and oil service engineering had the highest weekly gains of 18.02% and 14.83%, while aerospace equipment II and military electronics II faced the largest declines of -15.78% and -8.45% [4][22] - The third-level industries showed gold and seeds leading with weekly increases of 18.22% and 15.02%, while aerospace equipment III and thermal power equipment had the largest drops of -15.78% and -9.93% [5][25] Macro Data - The manufacturing PMI for January was reported at 49.3%, indicating a contraction in manufacturing activity, with the production index at 50.6% showing slight expansion [6][27][28] - The new orders index fell to 49.2%, suggesting a slowdown in market demand across various sectors [28] Investment Recommendations - The report anticipates a stable economic environment in 2026, supported by proactive fiscal policies and moderate monetary easing, which is expected to sustain a "slow bull" market for A-shares [8][31] - Short-term market expectations remain strong, particularly in sectors related to "anti-involution," new productivity in AI and technology, and agriculture, which are expected to benefit from central bank policies [8][31]

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10]. Core Insights - The medical and biological sector experienced a decline of 3.31% this week, ranking 22nd among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index rose by 0.08%, indicating that the medical sector underperformed by 3.39 percentage points [2][12]. - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, 2026, aiming to enhance drug research, registration, and production management, thereby fostering innovation in the pharmaceutical industry [5][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 33.87X, with a Price-to-Book (PB) ratio of 3.43X, reflecting a decrease from the previous week [4][30]. Summary by Sections Industry Performance - The medical services sub-sector closed at 7122.75 points, down 4.15% this week, while the overall medical and biological sector fell by 3.31% [2][24]. - Notable performers in the medical services sector included Tigermed (+4.3%) and Prasis (+2.3%), while underperformers included Bid Pharma (-15.2%) and Haoyuan Pharma (-12.8%) [3][28]. Valuation Metrics - The medical services sector's PE ratio has decreased by 1.43X from the previous week, while the PB ratio has dropped by 0.15X [4][30]. - The maximum and minimum PE ratios over the past year were 41.13X and 28.46X, respectively, while the PB ratios ranged from 4.00X to 2.48X [30][49]. Regulatory Developments - The new drug administration regulations aim to support drug innovation and streamline the drug approval process, including provisions for market exclusivity for certain drugs [5][63]. - The regulations are expected to stimulate the CXO (Contract Research Organization) industry, enhancing demand for preclinical research and clinical trials [9][63]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharma, as well as companies in the consumer healthcare sector like Aier Eye Hospital and Dian Diagnostics, which are expected to see improvements in profitability [10][64].

Investment Rating - The industry rating is upgraded to "Overweight" from "Buy" due to rapid valuation increases and optimistic expectations reflected in stock prices [5]. Core Insights - The tungsten industry has shown strong market performance with a significant valuation increase, outperforming the benchmark index [2]. - Domestic tungsten prices have reached historical highs, driven by tight supply at the mining level and rising prices for long-term contracts [3]. - The supply chain remains constrained by tight raw material availability, leading to limited demand release and reduced transaction volumes [6]. Price Statistics - In January 2026, the average price of 65% black tungsten concentrate increased by 26.69% month-on-month to 510,600 CNY/ton, and by 254.75% year-on-year, with the increase from December 2025 expanding by 72.05 percentage points [5]. - The average price of 65% white tungsten concentrate rose by 26.76% month-on-month to 508,700 CNY/ton, with a year-on-year increase of 256.66% [5]. - The average price of ammonium paratungstate (APT) increased by 26.2% month-on-month to 751,400 CNY/ton, with a year-on-year increase of 254.53% [5]. Supply and Demand Dynamics - The supply of tungsten concentrate has slightly decreased, with weekly production dropping from 1,880 tons to 1,870 tons [6]. - The production of APT is estimated to increase by 5.88% in January 2026, but the overall supply remains constrained due to tight raw material availability [6]. - Demand is primarily driven by essential needs, with limited room for growth as rising raw material prices suppress downstream replenishment [6]. Profitability Analysis - Mining profits are expanding due to resource scarcity and price increases, with simulated gross profit for tungsten concentrate reaching 334,900 CNY/ton, a month-on-month increase of 40.77% [6]. - The midstream refining sector is also seeing steady profit growth, while downstream processing and alloy sectors are experiencing profit pressure due to lagging price transmission [6]. Investment Recommendations - The long-term outlook for the tungsten industry is positive, with supply constraints expected to strengthen due to declining ore grades and increased mining costs [6]. - Short-term expectations indicate that tight supply conditions will likely persist, supporting strong tungsten concentrate prices [6]. - Continued focus is recommended on companies with rich tungsten resources and integrated industrial layouts, particularly those investing in deep processing and emerging product areas [7].